Purple Biotech Ltd. Updates Corporate Presentation
Ticker: PPBT · Form: 6-K · Filed: Sep 16, 2025 · CIK: 1614744
Sentiment: neutral
Topics: corporate-update, presentation, foreign-private-issuer
TL;DR
Purple Biotech dropped a new deck on 9/15 - check it for the latest.
AI Summary
On September 15, 2025, Purple Biotech Ltd. released an updated corporate presentation titled "Purple Biotech Corporate presentation September 2025". This filing is a Report of Foreign Private Issuer under the Securities Exchange Act of 1934.
Why It Matters
Investors can review the latest company strategy and outlook directly from management.
Risk Assessment
Risk Level: low — This filing is an informational update and does not contain significant financial or operational changes.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the report
- September 15, 2025 (date) — Date of issuance of the corporate presentation
- Purple Biotech Corporate presentation September 2025 (document) — Title of the updated presentation
- 001-37643 (company) — SEC Commission File Number
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to report the issuance of an updated company presentation titled "Purple Biotech Corporate presentation September 2025" on September 15, 2025.
What is the name of the company filing this report?
The company filing this report is Purple Biotech Ltd.
When was the updated corporate presentation issued?
The updated corporate presentation was issued on September 15, 2025.
What is the SEC Commission File Number for Purple Biotech Ltd.?
The SEC Commission File Number for Purple Biotech Ltd. is 001-37643.
What form is Purple Biotech Ltd. filing?
Purple Biotech Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2025-09-15 19:20:16
Filing Documents
- ea0257470-6k_purple.htm (6-K) — 14KB
- ea025747001ex99-1_purple.htm (EX-99.1) — 73KB
- ex99-1_001.jpg (GRAPHIC) — 814KB
- ex99-1_002.jpg (GRAPHIC) — 1417KB
- ex99-1_003.jpg (GRAPHIC) — 732KB
- ex99-1_004.jpg (GRAPHIC) — 514KB
- ex99-1_005.jpg (GRAPHIC) — 519KB
- ex99-1_006.jpg (GRAPHIC) — 769KB
- ex99-1_007.jpg (GRAPHIC) — 884KB
- ex99-1_008.jpg (GRAPHIC) — 786KB
- ex99-1_009.jpg (GRAPHIC) — 592KB
- ex99-1_010.jpg (GRAPHIC) — 617KB
- ex99-1_011.jpg (GRAPHIC) — 796KB
- ex99-1_012.jpg (GRAPHIC) — 794KB
- ex99-1_013.jpg (GRAPHIC) — 834KB
- ex99-1_014.jpg (GRAPHIC) — 455KB
- ex99-1_015.jpg (GRAPHIC) — 632KB
- ex99-1_016.jpg (GRAPHIC) — 714KB
- ex99-1_017.jpg (GRAPHIC) — 826KB
- ex99-1_018.jpg (GRAPHIC) — 715KB
- ex99-1_019.jpg (GRAPHIC) — 834KB
- ex99-1_020.jpg (GRAPHIC) — 777KB
- ex99-1_021.jpg (GRAPHIC) — 692KB
- ex99-1_022.jpg (GRAPHIC) — 616KB
- ex99-1_023.jpg (GRAPHIC) — 615KB
- ex99-1_024.jpg (GRAPHIC) — 581KB
- ex99-1_025.jpg (GRAPHIC) — 566KB
- ex99-1_026.jpg (GRAPHIC) — 608KB
- ex99-1_027.jpg (GRAPHIC) — 581KB
- ex99-1_028.jpg (GRAPHIC) — 665KB
- ex99-1_029.jpg (GRAPHIC) — 795KB
- ex99-1_030.jpg (GRAPHIC) — 694KB
- ex99-1_031.jpg (GRAPHIC) — 780KB
- ex99-1_032.jpg (GRAPHIC) — 359KB
- ex99-1_033.jpg (GRAPHIC) — 732KB
- ex99-1_034.jpg (GRAPHIC) — 460KB
- ex99-1_035.jpg (GRAPHIC) — 705KB
- ex99-1_036.jpg (GRAPHIC) — 380KB
- ex99-1_037.jpg (GRAPHIC) — 572KB
- ex99-1_038.jpg (GRAPHIC) — 455KB
- ex99-1_039.jpg (GRAPHIC) — 610KB
- ex99-1_040.jpg (GRAPHIC) — 521KB
- ex99-1_041.jpg (GRAPHIC) — 569KB
- ex99-1_042.jpg (GRAPHIC) — 606KB
- ex99-1_043.jpg (GRAPHIC) — 723KB
- ex99-1_044.jpg (GRAPHIC) — 635KB
- ex99-1_045.jpg (GRAPHIC) — 651KB
- ex99-1_046.jpg (GRAPHIC) — 254KB
- ex99-1_047.jpg (GRAPHIC) — 837KB
- ex99-1_048.jpg (GRAPHIC) — 421KB
- ex99-1_049.jpg (GRAPHIC) — 681KB
- ex99-1_050.jpg (GRAPHIC) — 597KB
- ex99-1_051.jpg (GRAPHIC) — 654KB
- ex99-1_052.jpg (GRAPHIC) — 711KB
- ex99-1_053.jpg (GRAPHIC) — 751KB
- ex99-1_054.jpg (GRAPHIC) — 418KB
- ex99-1_055.jpg (GRAPHIC) — 853KB
- ex99-1_056.jpg (GRAPHIC) — 710KB
- 0001213900-25-087788.txt ( ) — 51162KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 15, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2